Keith Goldan
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Keith Goldan
Keith Goldan is recorded as CFO at Option Therapeutics Inc. (OPTN) and CFO at Syndax Pharmaceuticals Inc (SNDX). The proxy statement of Syndax Pharmaceuticals Inc reports total compensation of $2,470,802 for Keith Goldan in fiscal 2025, including a base salary of $516,900. Disclosed compensation is on record for 4 fiscal years. Keith Goldan has spoken on 20 earnings calls across 2 companies, most recently for Syndax Pharmaceuticals Inc on August 4, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Syndax Pharmaceuticals Inc
Other people whose current roles at this company are on record from its filings.
- Michael A. Metzger CEO, Board Member
- Michael Metzger CEO
- Daphne Karydas CFO
- Keith A. Goldan CFO
- Luke J. Albrecht General Counsel
- Aleksandra Rizo, M.D., Ph.D. Board Member
- Martin H. Huber, M.D. Board Member
- Pierre Legault Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $516,900 | $2,470,802 |
| 2024 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $497,000 | $2,824,133 |
| 2023 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $470,300 | $2,826,034 |
| 2022 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $249,900 | $2,992,538 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.